Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial. - Wikidata - wikimedia - TriplyDB

Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial.

Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial.

http://www.wikidata.org/entity/Q37106561

about

Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility Pioglitazone increases whole body insulin sensitivity in obese, insulin-resistant rhesus monkeys Peroxisome proliferator-activated receptor-(gamma) receptor ligand partially prevents the development of endometrial explants in baboons: a prospective, randomized, placebo-controlled study.Identification and treatment of metabolic complications in pediatric obesity.Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis.Effects of thiazolidinediones on polycystic ovary syndrome: a meta-analysis of randomized placebo-controlled trials.Hirsutism: an evidence-based treatment update.Assessing and treating insulin resistance in women with polycystic ovarian syndrome The Role of Metformin in Metabolic Disturbances during Pregnancy: Polycystic Ovary Syndrome and Gestational Diabetes Mellitus.Drospirenone/ethinyl estradiol versus rosiglitazone treatment in overweight adolescents with polycystic ovary syndrome: comparison of metabolic, hormonal, and cardiovascular risk factors.Polycystic ovary syndrome: chemical pharmacotherapy.Medical management of metabolic dysfunction in PCOS.Activation of G proteins by GIV-GEF is a pivot point for insulin resistance and sensitivity.Effects of insulin-sensitizing agents and insulin resistance in women with polycystic ovary syndrome Insulin and hyperandrogenism in women with polycystic ovary syndrome.Pioglitazone counteracts the tumor necrosis factor-α inhibition of follicle-stimulating hormone-induced follicular development and estradiol production in an in vitro mouse preantral follicle culture system.Evaluating the effect of insulin sensitizers metformin and pioglitazone alone and in combination on women with polycystic ovary syndrome: An RCT.Targeting insulin sensitivity in the treatment of polycystic ovary syndrome.Thiazolinedione treatment in PCOS--an update.Polycystic ovary syndrome: an overview.Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society.The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus.Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.Effects of placebo-controlled insulin-sensitizing drugs on hormonal parameters in polycystic ovary syndrome patients: A network meta-analysis.Serum adiponectin is independently associated with the metabolic syndrome in Hong Kong, Chinese women with polycystic ovary syndrome.Mechanistic links between oxidative/nitrosative stress and tumor necrosis factor alpha in letrozole-induced murine polycystic ovary: biochemical and pathological evidences for beneficial effect of pioglitazone.Low circulating adiponectin levels in women with polycystic ovary syndrome: an updated meta-analysis.Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS.

P2860

Q24197673-94CA19BE-09BE-4D08-92F9-E7965489A2AD Q24240654-753E402D-46D8-4540-9835-645FBE2AB129 Q27307174-9C82B4DA-E451-4C53-BC36-C8ADB8847C72 Q33772312-D223B6A2-A352-4771-B0A1-9B44C337D253 Q33893011-5F44E5B5-26AB-480B-970A-9143E8795F4F Q34148029-C314A16E-9754-4464-8D71-F97ADF309207 Q34397685-F06C91D4-8BB0-4717-94FE-C0481A24768C Q34422575-1FDA2553-D69D-4D3F-87EC-6ACA72A9E042 Q34878055-16516BDB-C0AB-4AAB-9FB4-9E7C770CC153 Q35100131-D9FEB10C-14CC-4521-A3E7-9A9366898E88 Q35468539-8A406062-CD46-49AC-A71F-F7B9AF083EE2 Q35639510-DE2D0BCF-0C24-48C8-968E-197B4B23487C Q36132055-DE2ACE56-F1E8-428B-9468-FC474EC7A1CF Q36274510-213D55E6-610A-48E0-895A-52204A737716 Q37022386-A48F9BC2-07F9-4EE3-9E19-894A7CA3C05D Q37355746-F5B3EE65-648B-40A5-A5CA-EE773A5F2CE0 Q37361691-E7195656-4F7A-4732-A51B-F997BD59EBC1 Q37547069-489D2622-0341-48C9-B489-9577301A9316 Q37570577-AD4199EB-05AD-4BF1-95E2-797ACE2682E9 Q37763184-B9BBF586-8567-4130-892B-69C1BB1B0CA4 Q37886072-B84BA9C5-5422-41A4-A9B8-189E6DCA46F6 Q37953819-072A7598-078D-4536-B413-9F3958F8ECFC Q38102596-59ABF3B2-12AB-466B-A356-8987BC0CB0CB Q47402228-49629B38-AB7A-43B8-807A-19F4DF81C54F Q47642633-1B8CAA2A-1223-45C0-9135-8DB407F786D6 Q47932338-46FEE00E-3C75-4C22-8A11-27EFB9F4793F Q51390042-4A56C17C-1A50-4CEC-9EE0-F8BE6DBD00F9 Q53134066-BD1D8384-EE4D-4CEB-94B8-A5FEF30B6789 Q53746829-08ABFF7B-13A8-4D27-B672-4431DCC27F83

P2860

Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial.

http://www.wikidata.org/entity/Q37106561

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Metabolic and hormonal changes ...... ebo-controlled clinical trial.

@en

Metabolic and hormonal changes ...... ebo-controlled clinical trial.

@nl

type

label

Metabolic and hormonal changes ...... ebo-controlled clinical trial.

@en

Metabolic and hormonal changes ...... ebo-controlled clinical trial.

@nl

prefLabel

Metabolic and hormonal changes ...... ebo-controlled clinical trial.

@en

Metabolic and hormonal changes ...... ebo-controlled clinical trial.

@nl

P1433

Q37106561-6B01A427-FCCA-4292-8F34-FE0AC7BF51A1

P1476

Q37106561-40300659-170A-4DDF-93D7-39EB8C7DEE5E

P2093

Q37106561-1120E9D3-1122-4342-B910-2325013CF841

Q37106561-5B971E2D-2DDA-478E-8134-F79F294C395D

Q37106561-6D1AE002-CC39-49ED-8780-E2DF17D8C656

Q37106561-D341A14C-32BE-4A91-8E86-9EB8769AF16C

Q37106561-DCD5CF37-53EF-417C-8B66-A7F7731FD845

Q37106561-F65400E5-CDE1-46F1-82DF-EAE25846B996

Q37106561-F6D5FD28-EDF2-412F-94A0-C856C9912040

Q37106561-FEB75302-E3E6-4BC5-A19E-5984F96F7D7C

P2860

Q37106561-01EC7880-5CCD-46ED-AB10-D1249A9FF782

Q37106561-20D2A4B6-C7B5-4002-8919-010E5AE72B19

Q37106561-22C69EFA-38F6-4733-BC8F-042AFA9A5B59

Q37106561-23FB9A44-CE7C-4D01-B60A-6070E0648D12

Q37106561-2D33E662-27E7-459B-AAFD-69415FA4BC73

Q37106561-333902F1-9221-48CF-AA16-4AD3C1E58C39

Q37106561-388A1C05-5387-4A4B-8026-D390782560DF

Q37106561-3E02B968-3B16-4EFF-831D-EE1FF6B8082C

Q37106561-418E9C85-8F5C-40BF-85E3-66C27D70F7E5

Q37106561-511F2B78-9F3B-4998-B026-38F115CE3712

P304

Q37106561-DB1F335F-6BCD-4675-A2B8-0263E2AB6ABA

P31

Q37106561-5FDA5BAA-17EE-4B60-BD42-7F5DF8E83D4A

P356

Q37106561-871BACEA-28B0-4F20-BE46-5E3F1D13A567

P407

Q37106561-7A8F8366-C07A-47D4-9F0E-F71E24514E2A

P433

Q37106561-15E30BA1-5703-4BA6-90E5-B28284FDC1B6

P478

Q37106561-D3BB8998-7194-47D5-91F2-7E864F67D6E2

P577

Q37106561-90DDB928-EBA2-452B-8691-E62E3A762752

P698

Q37106561-E1E74CE2-66BC-41E9-89FA-0DB765BEA590

P921

Q37106561-29D84BBB-4071-421B-9581-F02FE05FA8AA

Q37106561-DC04CEC1-A89F-4DE5-BCBE-F866AD096D0C

P932

Q37106561-1A2AB744-B53A-4BD6-8297-69180FFB654E

P356

P1433

The Journal of Clinical Endocrinology and Metabolism

P1476

Metabolic and hormonal changes ...... ebo-controlled clinical trial.

@en

P2093

Paivi Burke

http://www.w3.org/2001/XMLSchema#string

Paul Clopton

http://www.w3.org/2001/XMLSchema#string

R Jeffrey Chang

http://www.w3.org/2001/XMLSchema#string

Robert R Henry

http://www.w3.org/2001/XMLSchema#string

Sunder Mudaliar

http://www.w3.org/2001/XMLSchema#string

Susan Phillips

http://www.w3.org/2001/XMLSchema#string

Theodore P Ciaraldi

http://www.w3.org/2001/XMLSchema#string

Vanita R Aroda

http://www.w3.org/2001/XMLSchema#string

P2860

Insulin augmentation of 17alpha-hydroxylase activity is mediated by phosphatidyl inositol 3-kinase but not extracellular signal-regulated kinase-1/2 in human ovarian theca cells.

Glucose clamp technique: a method for quantifying insulin secretion and resistance.

Intracellular glucose oxidation and glycogen synthase activity are reduced in non-insulin-dependent (type II) diabetes independent of impaired glucose uptake.

The prevalence and features of the polycystic ovary syndrome in an unselected population.

Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women.

Thiazolidinediones for treatment of polycystic ovary syndrome.

Evidence for insulin suppression of baseline luteinizing hormone in women with polycystic ovarian syndrome and normal women.

Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program

Association of adiponectin with coronary heart disease and mortality: the Rancho Bernardo study

Role of cytochrome P450c17 in polycystic ovary syndrome.

P304

469-476

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/JC.2008-1133

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P577

2008-11-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18984667

http://www.w3.org/2001/XMLSchema#string

P921

polycystic ovary syndrome

P932

2646515

http://www.w3.org/2001/XMLSchema#string